Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | PIM1 | P11309 | 4/20 | 0.63 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.63 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.63 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.59 |
| ▸ | GABRP | O00591 | 5/20 | 0.56 |
| ▸ | GABRD | O14764 | 5/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 5/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117853 | 0.87 | GABRP (0.53) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL18397901 | 0.87 | AKR1B1 (0.69) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL15265273 | 0.85 | CA12 (0.56) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL15265359 | 0.83 | GABRP (0.49) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL8117167 | 0.81 | KDM4E (0.58) | ALDH1A1CSNK2A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL18144902 | 0.81 | ALDH1A1 (0.69) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL2976354 | 0.81 | AKR1B1 (0.76) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL4256569 | 0.81 | ALDH1A1 (0.69) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL379054 | 0.80 | ALDH1A1 (0.67) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 | |
| SCHEMBL2318176 | 0.80 | ALDH1A1 (0.67) | ALDH1A1PIM1CSNK2A1KDM4ECSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753560-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-12-23 | — | — | EP | claimed |
| CN-1863795-B | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | HANMI PHARM IND CO LTD | 2011-05-18 | — | — | CN | claimed |
| EP-1678162-B1 | P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM IND CO LTD (KR) | 2010-04-28 | — | — | EP | claimed |
| US-7625926-B2 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | HANMI PHARM. CO., LTD (KR) | 2009-12-01 | — | — | US | claimed |
| EP-1678162-A4 | P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM IND CO LTD (KR) | 2008-07-02 | — | — | EP | claimed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | claimed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | claimed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | claimed |
| EP-1711490-A4 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM IND CO LTD (KR) | 2007-04-04 | — | — | EP | claimed |
| US-20070072900-A1 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | HANMI PHARM. CO., LTD. (KR) | 2007-03-29 | — | — | US | claimed |
| CN-1863795-A | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | HANMI PHARM IND CO LTD (KR) | 2006-11-15 | — | — | CN | claimed |
| EP-1711490-A1 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Hanmi Pharm. Co., Ltd. (KR) | 2006-10-18 | — | — | EP | claimed |
| EP-1678162-A1 | P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Hanmi Pharm. Co., Ltd. (KR) | 2006-07-12 | — | — | EP | claimed |
| WO-2005033097-A1 | P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2005-04-14 | — | — | WO | claimed |
| WO-2005033101-A1 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2005-04-14 | — | — | WO | claimed |
| WO-2024217531-A1 | CYP11A1 INHIBITORS AND USE THEREOF | 西藏海思科制药有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-115536644-B | Application of chromone-2-formamide compound in preparation of hypoglycemic drugs and preparation method thereof | 广西民族大学 | 2024-09-03 | — | — | CN | disclosed |
| WO-2005033097-A1 | P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2005-04-14 | — | — | WO | disclosed |
| US-6552054-B1 | For prophylaxis and therapy of bone diseases and chondropathy | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-1211251-A1 | CHROMONE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | ALDH1A1 2000/4885PIM1 4635/4885CSNK2A1 1238/4885 |
| US-20070072900-A1 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | ABCB1, ABCG2, ABCB11 | ALDH1A1 1108/4885PIM1 614/4885CSNK2A1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.